Anthropometric indexes, insulin resistance, and serum leptin and lipid levels in women with cryptogenic epilepsy receiving topiramate treatment

Journal of Clinical Neuroscience

Volumn 17, Issue 10, 2010, Pages 1256-1259

  Genc, Bulent Oguz ^a   Dogan, Ebru Apaydin ^a   Dogan, Umuttan ^a   Genc, Emine ^a  

^a SELCUK UNIVERSITY   (Turkey)

Author keywords

Body mass index; HDL cholesterol; Insulin resistance; Leptin topiramate; Waist circumference

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LIPID; TOPIRAMATE;

ADOLESCENT; ADULT; ANTHROPOMETRY; ARTICLE; BODY MASS; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DRUG EFFECT; EPILEPSY; FEMALE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; PRIORITY JOURNAL; VASCULAR DISEASE; WAIST CIRCUMFERENCE;

ADOLESCENT; ADULT; ANTHROPOMETRY; ANTICONVULSANTS; BODY MASS INDEX; BODY WEIGHT; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPILEPSY; FEMALE; FRUCTOSE; HUMANS; INSULIN RESISTANCE; LEPTIN; LIPID METABOLISM; YOUNG ADULT;

EID: 77955657707     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2010.01.045     Document Type: Article

References (31)

1. F.J.E. Vajda Pharmacotherapy of epilepsy: new armamentarium, new issues J Clin Neurosci 14 2007 813 823
2. J.F. Annegers, W.A. Hauser, and S.B. Shirts Heart disease mortality and morbidity in patients with epilepsy Epilepsia 25 1984 699 704
3. A. Gaitatzis, K. Carroll, and A. Majeed The epidemiology of the comorbidity of epilepsy in the general population Epilepsia 45 2004 1613 1622
4. L. Nilsson, T. Tomson, and B.Y. Farahmand Cause-specific mortality in epilepsy: a cohort study of more than 9,000 patients once hospitalized for epilepsy Epilepsia 38 1997 1062 1068
5. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy Epilepsia 30 1989 389 399
6. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee World Health Organ Tech Rep Ser 854 1995 1 452
7. K.G. Alberti, P. Zimmet, and J. Shaw IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition Lancet 366 2005 1059 1062
8. D.R. Matthews, J.P. Hosker, and A.S. Rudenski Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
9. E. Bonora, G. Targher, and M. Alberiche Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity Diabetes Care 23 2000 57 63
10. J. Rosenstock, P. Hollander, and K.M. Gadde A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients Diabetes Care 30 2007 1480 1486
11. K.M. Klein, F. Theisen, and S. Knake Topiramate, nutrition and weight change: a prospective study J Neurol Neurosurg Psychiatry 79 2008 590 593
12. E. Ben-Menachem, M. Axelsen, and E.H. Johanson Predictors of weight loss in adults with topiramate-treated epilepsy Obes Res 11 2003 556 562
13. G.A. Bray, P. Hollander, and S. Klein A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity Obes Res 11 2003 722 733
14. A. Menke, P. Muntner, and R.P. Wildman Measures of adiposity and cardiovascular disease risk factors Obesity (Silver Spring) 15 2007 785 795
15. S. Yusuf, S. Hawken, and S. Ounpuu Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 2004 937 952
16. V. Khanna, S. Arumugam, and S. Roy Topiramate and type 2 diabetes: an old wine in a new bottle Expert Opin Ther Targets 12 2008 81 90
17. B. Eliasson, S. Gudbjornsdottir, and J. Cederholm Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial Int J Obes (Lond) 31 2007 1140 1147
18. J.J. Wilkes, M.T. Nguyen, and G.K. Bandyopadhyay Topiramate treatment causes skeletal muscle insulin sensitization and increased Acrp30 secretion in high-fat-fed male Wistar rats Am J Physiol Endocrinol Metab 289 2005 E1015 E1022
19. A. Halpern, and M.C. Mancini Diabesity: are weight loss medications effective? Treat Endocrinol 4 2005 65 74
20. J.M. Friedman, and J.L. Halaas Leptin and the regulation of body weight in mammals Nature 395 1998 763 770
21. F.M. Theisen, S. Beyenburg, and S. Gebhardt A prospective study of body weight and serum leptin levels in patients treated with topiramate Clin Neuropharmacol 31 2008 226 230
22. J. Lalonde, P. Samson, and S. Poulin Additive effects of leptin and topiramate in reducing fat deposition in lean and obese ob/ob mice Physiol Behav 80 2004 415 420
23. S. Mintzer, and R.T. Mattson Should enzyme-inducing antiepileptic drugs be considered first-line agents? Epilepsia 50 Suppl. 8 2009 42 50
24. J.I. Isojärvi, A.J. Pakarinen, and W. Myllylä Serum lipid levels during carbamazepine medication Arch Neurol 50 1993 590 593
25. T. Nikolaos, G. Stylianos, and N. Chryssoula The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy Med Sci Monit 10 2004 MT50 MT52
26. E.P. Calandre, C. Rodriquez-Lopez, and A. Blazquez Serum lipids, lipoproteins and apolipoproteins A and B in epileptic patients treated with valproic acid, carbamazepine or phenobarbital Acta Neurol Scand 83 1991 250 253
27. J.M. Eiris, S. Lojo, and M.C. Del Rio Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy Neurology 45 1995 1155 1157
28. A. Verrotti, S. Domizio, and B. Angelozzi Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants J Paediatr Child Health 33 1997 242 245
29. S. Mintzer, C.T. Skidmore, and C.J. Abidin Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein Ann Neurol 65 2009 448 456
30. P.N. Patsalos, W. Froscher, and F. Pisani The importance of drug interactions in epilepsy therapy Epilepsia 43 2002 365 385
31. S. Lamon-Fava, P.W. Wilson, and E.J. Schaefer Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study Arterioscler Thromb Vasc Biol 16 1996 1509 1515